Modulating Angiogenesis by Proteomimetics of Vascular Endothelial Growth Factor
Overview
Affiliations
Angiogenesis, formation of new blood vessels from the existing vascular network, is a hallmark of cancer cells that leads to tumor vascular proliferation and metastasis. This process is mediated through the binding interaction of VEGF-A with VEGF receptors. However, the balance between pro-angiogenic and anti-angiogenic effect after ligand binding yet remains elusive and is therefore challenging to manipulate. To interrogate this interaction, herein we designed a few sulfono-γ-AA peptide based helical peptidomimetics that could effectively mimic a key binding interface on VEGF (helix-α1) for VEGFR recognition. Intriguingly, although both sulfono-γ-AA peptide sequences and bound to VEGF receptors tightly, in vitro angiogenesis assays demonstrated that potently inhibited angiogenesis, whereas activated angiogenesis effectively instead. Our findings suggested that this distinct modulation of angiogenesis might be due to the result of selective binding of to VEGFR-1 and to VEGFR-2, respectively. These molecules thus provide us a key to switch the angiogenic signaling, a biological process that balances the effects of pro-angiogenic and anti-angiogenic factors, where imbalances lead to several diseases including cancer. In addition, both and exhibited remarkable stability toward proteolytic hydrolysis, suggesting that and are promising therapeutic agents for the intervention of disease conditions arising due to angiogenic imbalances and could also be used as novel molecular switching probes to interrogate the mechanism of VEGFR signaling. The findings also further demonstrated the potential of sulfono-γ-AA peptides to mimic the α-helical domain for protein recognition and modulation of protein-protein interactions.
Unnatural foldamers as inhibitors of Aβ aggregation stabilizing the Aβ helix.
Liu H, Zhao X, Chen J, Win Y, Cai J Chem Commun (Camb). 2025; .
PMID: 40035705 PMC: 11878269. DOI: 10.1039/d4cc05280c.
Yang J, Yuan J, Wen Y, Wu L, Liao J, Qi H World J Stem Cells. 2025; 17(1):98349.
PMID: 39866893 PMC: 11752458. DOI: 10.4252/wjsc.v17.i1.98349.
Exploring the seas for cancer cures: the promise of marine-derived bioactive peptide.
Rafieezadeh D, Abbaspour M Int J Biochem Mol Biol. 2024; 15(4):100-106.
PMID: 39309615 PMC: 11411150. DOI: 10.62347/JGQA3746.
Are peptidomimetics the compounds of choice for developing new modulators of the JAK-STAT pathway?.
Cugudda A, La Manna S, Marasco D Front Immunol. 2024; 15:1406886.
PMID: 38983855 PMC: 11232365. DOI: 10.3389/fimmu.2024.1406886.
Helical sulfonyl-γ-AApeptides for the inhibition of HIV-1 fusion and HIF-1α signaling.
Zhao X, Liu H, Zhang J, Cai J RSC Med Chem. 2024; 15(5):1418-1423.
PMID: 38784464 PMC: 11110726. DOI: 10.1039/d4md00110a.